Back to News
Market Impact: 0.32
Roche's Susvimo Wins EU Approval For Neovascular Age-Related Macular Degeneration
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
The European Commission approved Roche's Susvimo (ranibizumab 100 mg/mL) to treat adults with neovascular age-related macular degeneration. The authorization expands Roche's commercial opportunity in the European ophthalmology market and is a positive regulatory milestone for the product.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
More News
- How the US midterm elections reflected resistance to data centres
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Bitcoin rebounds to $76,000, but $1.3 billion ETF exodus tests recovery